Navigation Links
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Date:9/22/2008

Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298) in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
2. BioMS Medical to present at UBS Global Life Sciences Conference
3. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. BioMS Medical Announces Second Quarter 2008 Results
7. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
8. BioMS Medical to present at BMO Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at Jefferies Healthcare Conference
11. BioMS Medical to present at 2008 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
(Date:10/20/2014)... 20, 2014 OncLive® ... Cancer Center at Thomas Jefferson University has joined ... the Strategic Alliance Partnership program, the Sidney Kimmel ... to raise awareness of the Center’s cutting-edge research ... projects. Clinicians and other health care professionals from ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is ... donor stem cells for dogs with osteoarthritis. Dr. McCarthy ... performed clinical stem cell therapy for 7 years. The ... a single injection of donor stem cells into one ... and inflammation in the treated joints. , Candidates ...
(Date:10/19/2014)... 20, 2014 OCTOBER 20-22, ... (ABIM). ABIM will take place at ... about ABIM 2014 is now available at ... representing companies and organizations from all over ... information on the latest products and developments ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... href="http://www.ambion.com/catalog/CatNum.php?1632"> Silencer , ... be readily adapted for labeling long dsRNA. ... for this application. See "<A , href="#visualizing">Visualizing ... experimintal data using dsRNA , labeled in ...
... , NAVIGATE THIS ARTICLE: <A , ... href="#3">RNA , Isolation, Probe Generation > <A , ... > <A , href="#5">Hybridization, , ... & Reprobing , , , , ...
... Ambion has ... siRNA synthesis and purification based on in vitro , ... (patent pending). This kit produces transfection-ready siRNA , ... researchers at the Salk Institute ...
Cached Biology Technology:Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 2Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 3Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 4Northern Analysis: The Basics 2Northern Analysis: The Basics 3Northern Analysis: The Basics 4Northern Analysis: The Basics 5Northern Analysis: The Basics 6Northern Analysis: The Basics 7Northern Analysis: The Basics 8Northern Analysis: The Basics 9Northern Analysis: The Basics 10Northern Analysis: The Basics 11Northern Analysis: The Basics 12Northern Analysis: The Basics 13Northern Analysis: The Basics 14Northern Analysis: The Basics 15Northern Analysis: The Basics 16Northern Analysis: The Basics 17Northern Analysis: The Basics 18Northern Analysis: The Basics 19Your Data: Silencing Neural Cell Adhesion Genes with In Vitro Transcribed siRNAs 2
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/15/2014)... PORT WASHINGTON, N.Y. , Oct. 15, 2014 ... in technology solutions for home and community-based care, ... the benefits of implementing Sandata,s Santrax® Electronic Visit ... Quality Care Services is a home health company ... Texas . ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... each living cell needs both to build new and ... a number of intracellular systems work in concert to ... damaged proteins. When proteins or peptides mutate, they can ... intracellular environment. In Huntington's disease (HD) the disease provoking ...
... Wildlife Conservation Society working in Iran has successfully fitted ... marking the first time this highly endangered population of ... found throughout the continent, Asiatic cheetahs now live only ... Kavir Desert. WCS's government partner in Iran, the Department ...
... An international group of scientists has announced a ... describe the activities of genes in living organisms. ... use to describe the complex events that occur ... host. Understanding these events is crucial for developing ...
Cached Biology News:Proteasome activator enhances survival of Huntington's disease neuronal model cells 2In Iran, cheetahs collared for the first time 2Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3
... RPMI 1640 with 2 mM L-glutamine and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)...
CELLine System cultivation flask (for secreted products)...
... StabilCoat Plus Microsphere/Microarray Stabilizer is an ... protein and other non-toxic chemicals in a ... 7.4. This product contains a ... as a preservative. StabilCoat Plus Stabilizer ...
Biology Products: